» Articles » PMID: 3885222

Proteolytic Modification of Human Complement Protein C9: Loss of Poly(C9) and Circular Lesion Formation Without Impairment of Function

Overview
Specialty Science
Date 1985 Apr 1
PMID 3885222
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

We have compared the ability of thrombin-cleaved C9 (C9n) with that of native C9 to produce tubular or ring-like poly(C9) and to express the classical complement lesion on target membranes. Three procedures were used to produce poly(C9): (i) limited proteolysis with trypsin, (ii) interaction with small unilamellar lipid vesicles, and (iii) incubation with a 2- to 4-fold molar excess of ZnCl2. In contrast to C9, which could be converted to tubular poly(C9), C9n was converted to smaller peptides by the first procedure and was aggregated into string-like poly(C9) by the other two methods. C9-depleted human serum (R-9 serum) was reconstituted with either C9 or C9n and these sera were then used to lyse sensitized sheep erythrocytes. Numerous classical complement lesions could be detected on ghost membranes obtained from cells lysed by C9-reconstituted R-9 serum but only a few on ghost membranes produced by C9n-reconstituted R-9 serum. C9n was shown to be hemolytically as active as C9 even when tested under "single-hit" conditions and it was about twice as efficient when compared with C9 in releasing sucrose and inulin from resealed ghosts. These results are interpreted to indicate that formation of the classical complement lesion is only incidental to lysis and not an obligatory event and that enlargement of the "functional pore size" of the complement lesion is not linked to formation of a circular membrane attack complex.

Citing Articles

Elucidating the Immune Evasion Mechanisms of , the Causative Agent of Lyme Disease.

Walter L, Surth V, Rottgerding F, Zipfel P, Fritz-Wolf K, Kraiczy P Front Immunol. 2019; 10:2722.

PMID: 31849943 PMC: 6902028. DOI: 10.3389/fimmu.2019.02722.


Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.

Fishelson Z, Kirschfink M Front Immunol. 2019; 10:752.

PMID: 31024572 PMC: 6467965. DOI: 10.3389/fimmu.2019.00752.


Topology of the membrane-bound form of complement protein C9 probed by glycosylation mapping, anti-peptide antibody binding, and disulfide modification.

Rossi V, Wang Y, Esser A Mol Immunol. 2010; 47(7-8):1553-60.

PMID: 20153530 PMC: 2849895. DOI: 10.1016/j.molimm.2010.01.013.


Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization.

Hu V, Nicholson-Weller A Proc Natl Acad Sci U S A. 1985; 82(16):5520-4.

PMID: 3860874 PMC: 391154. DOI: 10.1073/pnas.82.16.5520.


The membrane attack complex of complement induces permeability changes via thresholds in individual cells.

Patel A, Campbell A Immunology. 1987; 60(1):135-40.

PMID: 3817867 PMC: 1453356.


References
1.
Stolfi R . Immune lytic transformation: a state of irreversible damage generated as a result of the reaction of the eighth component in the guinea pig complement system. J Immunol. 1968; 100(1):46-54. View

2.
Humphrey J, Dourmashkin R . The lesions in cell membranes caused by complement. Adv Immunol. 1969; 11:75-115. DOI: 10.1016/s0065-2776(08)60478-2. View

3.
LACHMANN P, Thompson R . Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J Exp Med. 1970; 131(4):643-57. PMC: 2138770. DOI: 10.1084/jem.131.4.643. View

4.
LACHMANN P, Munn E, Weissmanng . Complement-mediated lysis of liposomes produced by the reactive lysis procedure. Immunology. 1970; 19(6):983-6. PMC: 1455672. View

5.
Hesketh T, Dourmashkin R, Payne S, Humphrey J, LACHMANN P . Lesions due to complement in lipid membranes. Nature. 1971; 233(5322):620-3. DOI: 10.1038/233620a0. View